Pipeline asset valuation: garbage in – garbage out

Methods of valuing pharmaceutical development-stage assets have been a perennial talking point for decades, and the advantages and disadvantages of each have been covered in numerous publications....
Learn More

The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More

Routes to European Commercialisation in Europe

Title: Routes to Commercialisation in Europe Author: Anna Casse, Managing Partner Abstract In the past it was not extraordinary for US biotech companies to develop drugs in the US and to launch them...
Learn More

NASH Bubble?

Title: NASH Bubble? Author: Peter G. Traber, MD Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) have been the subject of intense interest in the biotech/pharma...
Learn More

How to start a biotech company

How to start a biotech company by Rob Johnson, Managing Partner and Jess Hearn, Consultant, at Alacrita
Learn More

How best to Prioritize the IP Portfolio in Universities, Charities and Research Funding Bodies?

by Saadia Basharat, PhD, Consultant, Alacrita  
Learn More
1